Detroit, MI – According to filings with the U.S. Securities and Exchange Commission, Seraph Biosciences is raising $2,500,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, James Shanley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Seraph Biosciences

By leveraging the principles of Raman Spectroscopy, Seraspec represents a paradigm shift away from current methods for screening and identification of dangerous bacterial, viral and fungal pathogens. Our patent pending technology and method of detection effectively eliminates the need for time-consuming and costly laboratory-based methods of specimen collection, processing and pathogen identification. Safety, efficiency, accuracy and profitability are simultaneously enhanced through a portable, point-of-care technology for real-time pathogen detection and identification. A higher power just got involved in the fight against infection.

To learn more about Seraph Biosciences, visit http://www.seraspec.com/

Contact:
James Shanley, President and Chief Executive Officer
313-759-8009
jshanley@seraspec.com
https://www.linkedin.com/in/jim-shanley-811319/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved